Cite
Irradiation plus myeloid-derived suppressor cell-targeted therapy for overcoming treatment resistance in immunologically cold urothelial carcinoma.
MLA
Yamamoto, Shoma, et al. “Irradiation plus Myeloid-Derived Suppressor Cell-Targeted Therapy for Overcoming Treatment Resistance in Immunologically Cold Urothelial Carcinoma.” British Journal of Cancer, vol. 128, no. 12, June 2023, pp. 2197–205. EBSCOhost, https://doi.org/10.1038/s41416-023-02244-8.
APA
Yamamoto, S., Kato, M., Takeyama, Y., Azuma, Y., Yukimatsu, N., Hirayama, Y., Otoshi, T., Yamasaki, T., Fujioka, M., Gi, M., Wanibuchi, H., & Uchida, J. (2023). Irradiation plus myeloid-derived suppressor cell-targeted therapy for overcoming treatment resistance in immunologically cold urothelial carcinoma. British Journal of Cancer, 128(12), 2197–2205. https://doi.org/10.1038/s41416-023-02244-8
Chicago
Yamamoto, Shoma, Minoru Kato, Yuji Takeyama, Yukari Azuma, Nao Yukimatsu, Yukiyoshi Hirayama, Taiyo Otoshi, et al. 2023. “Irradiation plus Myeloid-Derived Suppressor Cell-Targeted Therapy for Overcoming Treatment Resistance in Immunologically Cold Urothelial Carcinoma.” British Journal of Cancer 128 (12): 2197–2205. doi:10.1038/s41416-023-02244-8.